(Q54564466)

1 June 2018

title

Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR. (English)

1 reference

1 June 2018

author

Federico Cappuzzo

series ordinal

2

1 reference

1 June 2018

author name string

Lorenza Landi

series ordinal

1

1 reference

1 June 2018

language of work or name

English

0 references

publication date

30 August 2011

1 reference

1 June 2018

Nature Reviews Clinical Oncology

published in

1 reference

1 June 2018

volume

8

1 reference

1 June 2018

issue

10

1 reference

1 June 2018

page(s)

571-573

1 reference

1 June 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.135

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.135

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.135

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.135

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.135

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.135

10.1038/NRCLINONC.2011.135

31 March 2020

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018